Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aristolochic acid-related renal cell carcinoma exhibits a distinct tumor-immune microenvironment favoring response to immune checkpoint blockade.

The Journal of pathology - 1 Dec 2024

Lin Po-Hung, Chan Jason Yongsheng, Guan Peiyong, Hong Jing Han, Lim Abner Herbert, Ng Cedric Chuan-Young, Yeong Joe Poh Sheng, Lee Jing Yi, Liu Wei, Lim Jeffrey Chun Tatt, Pang See-Tong, Teh Bin Tean

Abstract excerpt

Immune checkpoint blockade (ICB) is currently the standard of care for metastatic renal cell carcinoma (RCC), but treatment responses remain unpredictable. Aristolochic acid (AA), a prevalent supplement additive in Taiwan, has been associated with RCC and induces signature mutations, although its effect on the tumor-immune microenvironment (TIME) is unclear. We aimed to investigate the immune profile of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Exome Sequencing

Share to Immune Checkpoint Inhibitors

Share to Kidney Neoplasms

Share to Mutation

Share to Tumor Microenvironment

Source

Identifiers

PMID: 39360336
DOI: 10.1002/path.6349

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aristolochic acid-related renal cell carcinoma exhibits a distinct tumor-immune microenvironment favoring response to immune checkpoint blockade.PMID 39360336Read ↗

Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure.Semantic proximity Read ↗

Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy decision-making for patients exposed to aristolochic acidSemantic proximity Read ↗

Current updates and future perspectives on the management of renal cell carcinoma.Semantic proximity Read ↗

Single-Cell Atlas of Renal Cell Carcinoma Brain Metastasis Uncovers Mechanisms of Immune Dysfunction and ResistanceSemantic proximity Read ↗

Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in PolandSemantic proximity Read ↗

Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaSemantic proximity Read ↗

Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.Semantic proximity Read ↗

Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia.Semantic proximity Read ↗

Aristolochic Acid in the Etiology of Renal Cell Carcinoma.Semantic proximity Read ↗

Determinants of anti-PD1 response and resistance in clear cell renal cell carcinomaSemantic proximity Read ↗

Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.